<DOC>
	<DOCNO>NCT03000309</DOCNO>
	<brief_summary>Sixteen week open label study apremilast combination topical steroid four week safety follow visit .</brief_summary>
	<brief_title>Use Apremilast Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy</brief_title>
	<detailed_description>This open label , 16 week study apremilast combination topical corticosteroid ( TCS ) . Twenty qualify subject enrol . Visits consist Baseline , 8 week , 16 week 20 week safety follow 4 week treatment . Subjects dose apremilast per label . Topical corticosteroid ( TCS ) use Week 4 per label use need basis Week 16 . Assessments include Static Physicians Global Assessment ( sPGA ) , Psoriasis Area Severity Index ( PASI ) , Psoriatic Body Surface Area ( BSA ) , Dermatology Life Quality Index ( DLQI ) , Assessment Pruritus , Patient Satisfaction questionnaire . Patient Global Assessment ( PtGA )</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must general good health judge investigator Female childbearing potential ( FCBP ) must negative pregnancy test screen Baseline . FCBP must use approved method contraception outline protocol . Male subject engage activity conception possible must use barrier contraception define protocol . 18 year age old Understand voluntarily sign Informed Consent Able adhere study visit schedule Moderate plaque type psoriasis define PGA 3 BSA 0f 510 % DLQI score 7 History uncontrolled plaque psoriasis either stable dose high potency topical steroid 2 week midpotency steroid 4 week within last 6 month Any clinically significant disease determine investigator major disease currently uncontrolled Any condition , include presence laboratory abnormality , would place subject unacceptable risk Prior history suicide attempt time subject 's lifetime prior screen randomization , major psychiatric illness require hospitalization within last 3 year Pregnant breastfeeding , FCBP willing use acceptable birth control method . Active substance abuse history substance abuse within 6 month prior screen . Malignancy history malignancy except fo treat ( cure ) basal cell squamous cell situ skin carcinoma , treat ( cure ) cervical intraepithelial neoplasia carcinoma situ cervix evidence recurrence within previous 5 year Has complete prescribe washout restricted treatment Known suspected allergy investigational product Other type psoriasis Prior history depression Prior use apremilast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>